drugset / Trial / NCT00556764

Development of Cognitive Assessment Tools in Parkinson Disease

NCT00556764 ↗

NaSingle-groupOpen-labelScreening

Summary

The main objectives of this protocol are as follows: 1. To assess the sensitivity and specificity of ANAM-PD in detecting cognitive status in patients with Parkinson disease (PD) and healthy controls (HC). 2. To validate the specific individual domains of the ANAM-PD cognitive battery by comparisons to available standardized cognitive evaluation scales administered to the patients with Parkinson disease with and healthy control subjects. 3. To evaluate the reliability of the ANAM-PD battery of tests by comparing repeated administrations of the ANAM-PD battery on a sub-set of subjects with Parkinson disease and healthy controls. 4. To characterize cholinergic neurotransmission through imaging the vesicular acetylcholine transporter binding with 123Iodobenzovesamicol (IBVM) and SPECT in PD patients and healthy controls.

Timeline

Start
2007-07
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject [123I] IBVM Diagnostic / imaging agent 4 unknown Other

Indications